Blog
RSS FeedPosted by Michael Wonder on 19 Mar 2020
ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...
Posted by Michael Wonder on 13 Mar 2020
ICER releases evidence report on treatments for sickle cell disease
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...
Posted by Michael Wonder on 25 Feb 2020
ICER issues final report and policy recommendations on acute treatments for migraine
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...
Posted by Michael Wonder on 20 Feb 2020
ICER releases draft evidence report on therapies for cystic fibrosis
20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 10 Jan 2020
ICER releases evidence report on acute treatments for migraine
10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...
Posted by Michael Wonder on 09 Jan 2020
ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis
9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...
Posted by Michael Wonder on 26 Nov 2019
ICER releases evidence report on JAK inhibitors to treat rheumatoid arthritis
26 November 2019 - Using adalimumab as the comparator, upadacitinib’s value-based price benchmark is between $44,000-$45,000 per year; at December 9 ...
Posted by Michael Wonder on 11 Oct 2019
ICER releases updated draft evidence report on rheumatoid arthritis therapies
11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...
Posted by Michael Wonder on 26 Sep 2019
ICER releases draft evidence report on rheumatoid arthritis therapies
26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 11 Sep 2019
ICER releases draft evidence report on diabetes therapies
11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 24 Jul 2019
ICER releases draft evidence report on additive cardiovascular disease therapies
24 July 2019 - Public comment period now open until 20 August 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis
11 April 2019 - Document open to public comment until 1 May 2019. ...
Posted by Michael Wonder on 09 Apr 2019
Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy
9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public ...